The global decoagulant market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of thrombotic disorders and cardiovascular diseases, which are major causes for blood clotting. The platelet aggregation inhibitors segment accounted for the largest share in the global decoagulant market in 2018 and is expected to maintain its dominance throughout the forecast period. Platelet aggregation inhibitors (PAI) accounted for a significant share in the global decoagulant market in 2018 and are expected to maintain their dominance throughout the forecast period. PAIs inhibit platelets from aggregating together by blocking their receptors on cell surfaces, thereby preventing them from sticking together and forming clots that can block blood vessels or cause heart attacks or strokes. Lomoleculaweight Heparin (LMWH) was one of the most commonly used PAIs due to its long-lasting effect on inhibiting platelets from aggregating together with other cells, thereby reducing risk of bleeding complications associated with other types of PAIs such as heparinoids or low molecular weight heparins (LMWHs). Direct thrombin inhibitor (DTI) was another type that gained popularity due to its ability to inhibit clot formation by directly targeting thrombin molecules responsible for clot formation without affecting other coagulation factors such as fibrinogen or factor VIIa like LMWHs do. Direct factor Xa inhibitors (DFXa) were also gaining traction due their ability not only target factor X but also factor IIa which helps prevent excessive bleeding after surgery while vitamin K antagonists (VKA) were used primarily as an alternative treatment option when patients cannot take oral anticoagulants because they have gastrointestinal problems or are allergic/sensitive towards them.
- Increasing prevalence of cardiovascular diseases.
- Increasing number of people suffering from diabetes.
- Growing awareness about the benefits of a healthy lifestyle.
- Increase in the number of people suffering from obesity.
- Increase in the number of people suffering from high blood pressure.
Industry Growth Insights published a new data on “Decoagulant Market”. The research report is titled “Decoagulant Market research by Types (Platelet aggregation inhibitors (PAI), Low-molecular-weight Heparin (LMWH), Direct thrombin inhibitor (DTI), Direct factor Xa inhibitors (DFXa), Vitamin K antagonists (VKA), Others), By Applications (VTE, ACS/MI, AF, Others), By Players/Companies Sanofi, Bayer, Boehringer Ingelheim, Johnson & Johnson, Genentech (Roche), AstraZeneca, Bristol-Myers Squibb, Aspen, Lilly, Otsuka, Pfizer, Daiichi Sankyo, The Medicines Company”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Decoagulant Market Research Report
By Type
Platelet aggregation inhibitors (PAI), Low-molecular-weight Heparin (LMWH), Direct thrombin inhibitor (DTI), Direct factor Xa inhibitors (DFXa), Vitamin K antagonists (VKA), Others
By Application
VTE, ACS/MI, AF, Others
By Companies
Sanofi, Bayer, Boehringer Ingelheim, Johnson & Johnson, Genentech (Roche), AstraZeneca, Bristol-Myers Squibb, Aspen, Lilly, Otsuka, Pfizer, Daiichi Sankyo, The Medicines Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Decoagulant Market Report Segments:
The global Decoagulant market is segmented on the basis of:
Types
Platelet aggregation inhibitors (PAI), Low-molecular-weight Heparin (LMWH), Direct thrombin inhibitor (DTI), Direct factor Xa inhibitors (DFXa), Vitamin K antagonists (VKA), Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
VTE, ACS/MI, AF, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Bayer
- Boehringer Ingelheim
- Johnson & Johnson
- Genentech (Roche)
- AstraZeneca
- Bristol-Myers Squibb
- Aspen
- Lilly
- Otsuka
- Pfizer
- Daiichi Sankyo
- The Medicines Company
Highlights of The Decoagulant Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Platelet aggregation inhibitors (PAI)
- Low-molecular-weight Heparin (LMWH)
- Direct thrombin inhibitor (DTI)
- Direct factor Xa inhibitors (DFXa)
- Vitamin K antagonists (VKA)
- Others
- By Application:
- VTE
- ACS/MI
- AF
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Decoagulant Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Decoagulant is a substance that helps to prevent blood from clotting.
Some of the major players in the decoagulant market are Sanofi, Bayer, Boehringer Ingelheim, Johnson & Johnson, Genentech (Roche), AstraZeneca, Bristol-Myers Squibb, Aspen, Lilly, Otsuka, Pfizer, Daiichi Sankyo, The Medicines Company.
The decoagulant market is expected to register a CAGR of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Decoagulant Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Decoagulant Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Decoagulant Market - Supply Chain
4.5. Global Decoagulant Market Forecast
4.5.1. Decoagulant Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Decoagulant Market Size (000 Units) and Y-o-Y Growth
4.5.3. Decoagulant Market Absolute $ Opportunity
5. Global Decoagulant Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Decoagulant Market Size and Volume Forecast by Type
5.3.1. Platelet aggregation inhibitors (PAI)
5.3.2. Low-molecular-weight Heparin (LMWH)
5.3.3. Direct thrombin inhibitor (DTI)
5.3.4. Direct factor Xa inhibitors (DFXa)
5.3.5. Vitamin K antagonists (VKA)
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Decoagulant Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Decoagulant Market Size and Volume Forecast by Application
6.3.1. VTE
6.3.2. ACS/MI
6.3.3. AF
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Decoagulant Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Decoagulant Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Decoagulant Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Decoagulant Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Decoagulant Demand Share Forecast, 2019-2026
9. North America Decoagulant Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Decoagulant Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Decoagulant Market Size and Volume Forecast by Application
9.4.1. VTE
9.4.2. ACS/MI
9.4.3. AF
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Decoagulant Market Size and Volume Forecast by Type
9.7.1. Platelet aggregation inhibitors (PAI)
9.7.2. Low-molecular-weight Heparin (LMWH)
9.7.3. Direct thrombin inhibitor (DTI)
9.7.4. Direct factor Xa inhibitors (DFXa)
9.7.5. Vitamin K antagonists (VKA)
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Decoagulant Demand Share Forecast, 2019-2026
10. Latin America Decoagulant Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Decoagulant Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Decoagulant Market Size and Volume Forecast by Application
10.4.1. VTE
10.4.2. ACS/MI
10.4.3. AF
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Decoagulant Market Size and Volume Forecast by Type
10.7.1. Platelet aggregation inhibitors (PAI)
10.7.2. Low-molecular-weight Heparin (LMWH)
10.7.3. Direct thrombin inhibitor (DTI)
10.7.4. Direct factor Xa inhibitors (DFXa)
10.7.5. Vitamin K antagonists (VKA)
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Decoagulant Demand Share Forecast, 2019-2026
11. Europe Decoagulant Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Decoagulant Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Decoagulant Market Size and Volume Forecast by Application
11.4.1. VTE
11.4.2. ACS/MI
11.4.3. AF
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Decoagulant Market Size and Volume Forecast by Type
11.7.1. Platelet aggregation inhibitors (PAI)
11.7.2. Low-molecular-weight Heparin (LMWH)
11.7.3. Direct thrombin inhibitor (DTI)
11.7.4. Direct factor Xa inhibitors (DFXa)
11.7.5. Vitamin K antagonists (VKA)
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Decoagulant Demand Share, 2019-2026
12. Asia Pacific Decoagulant Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Decoagulant Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Decoagulant Market Size and Volume Forecast by Application
12.4.1. VTE
12.4.2. ACS/MI
12.4.3. AF
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Decoagulant Market Size and Volume Forecast by Type
12.7.1. Platelet aggregation inhibitors (PAI)
12.7.2. Low-molecular-weight Heparin (LMWH)
12.7.3. Direct thrombin inhibitor (DTI)
12.7.4. Direct factor Xa inhibitors (DFXa)
12.7.5. Vitamin K antagonists (VKA)
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Decoagulant Demand Share, 2019-2026
13. Middle East & Africa Decoagulant Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Decoagulant Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Decoagulant Market Size and Volume Forecast by Application
13.4.1. VTE
13.4.2. ACS/MI
13.4.3. AF
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Decoagulant Market Size and Volume Forecast by Type
13.7.1. Platelet aggregation inhibitors (PAI)
13.7.2. Low-molecular-weight Heparin (LMWH)
13.7.3. Direct thrombin inhibitor (DTI)
13.7.4. Direct factor Xa inhibitors (DFXa)
13.7.5. Vitamin K antagonists (VKA)
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Decoagulant Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Decoagulant Market: Market Share Analysis
14.2. Decoagulant Distributors and Customers
14.3. Decoagulant Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Boehringer Ingelheim
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Genentech (Roche)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. AstraZeneca
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bristol-Myers Squibb
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Aspen
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Lilly
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Otsuka
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Pfizer
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Daiichi Sankyo
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. The Medicines Company
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook